Read Zacks_Analysts' blog in RSS
August 11, 2010
Share This
CryoPatch has been processed leveraging CryoLife’s proprietary SynerGraft technology, which is designed to remove allogeneic (genetically distinct) donor cells and cellular remnants from tissue. Since its launch, this specially processed tissue has broadened the application of the SynerGraft technology in additional human tissues and cells.
In contrast to conventionally processed pulmonary cardiac tissues, CryoPatch SG mitigates the risk of alloantibodies (an intrinsic component of the immune response to organ transplants) as measured by the Panel Reactive Antibody (PRA) blood test conducted on patients awaiting a transplant.
Patients with high PRA score are less likely to receive transplants given the high risk of rejection. As such, prevention of high PRA is critical for receivers of CryoPatch SG, who eventually require a heart transplant.
CryoLife is a leader in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries across the U.S. and Canada. Increased shipment of its heart valve products and cardiac patches contributed to a mid single-digit growth in cardiac revenues for first-half fiscal 2010.
The self-life expansion of CryoPatch SG should broaden its addressable market by means of covering additional patients. Moreover, this will facilitate the hospitals to streamline tissue inventory management and simplify their purchase decisions. The U.S. market for CryoPatch SG and related products for the repair or reconstruction of RVOT is estimated at roughly $15 million.
Read the full analyst report on "CRY"
Zacks Investment Research